Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gold

Showing results (711-720 of 721) with videos related to

Pageof 73
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
JAMA Surgery|July 2, 2025
Rizedisben in Minimally Invasive Surgery: A Nonrandomized Clinical TrialSamuel A Gold, Maria M Pere, Melissa Assel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2023
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E TrialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 13, 2021
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyApar Kishor P Ganti, Billy W Loo, Michael Bassetti, et al.
Journal of Lower Genital Tract Disease|September 28, 2017
Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United StatesNicolas Wentzensen, L Stewart Massad, Edward J Mayeaux, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026Apar Kishor P Ganti, Billy W Loo, Shahed Badiyan, et al.
Pageof 73

Showing results (711-720 of 721) with videos related to

Sort By:
Pageof 73
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
JAMA Surgery|July 2, 2025
Rizedisben in Minimally Invasive Surgery: A Nonrandomized Clinical TrialSamuel A Gold, Maria M Pere, Melissa Assel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2023
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E TrialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 13, 2021
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyApar Kishor P Ganti, Billy W Loo, Michael Bassetti, et al.
Journal of Lower Genital Tract Disease|September 28, 2017
Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United StatesNicolas Wentzensen, L Stewart Massad, Edward J Mayeaux, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026Apar Kishor P Ganti, Billy W Loo, Shahed Badiyan, et al.
Pageof 73